Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-adjusted Brequinar in AML
NCT03760666Phase 2Terminated
- Sponsor
- Clear Creek Bio
- Start
- Dec 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brequinar sodium in acute myeloid leukemia (AML), T-cell leukemia, mixed phenotype acute leukemia (MPAL), sponsored by Clear Creek Bio. Started Dec 2018; status: terminated.
02
Drugs
brequinar sodium
03
Conditions
acute myeloid leukemia (AML)T-cell leukemiamixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT03760666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03760666.